Cargando…
Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea
Purpose: This regulatory post-marketing surveillance (PMS) study was performed to evaluate the safety and effectiveness of regorafenib on Korean patients with colorectal cancer (CRC), gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in a real-world clinical setting. Methods...
Autores principales: | Beom, Seung-Hoon, Bae, Ki Beom, Zang, Dae Young, Bae, Joohee, Hwang, In Gyu, Kang, Hye Jin, Woo, In Sook, Shim, Byoung Yong, Bae, Byung-Noe, Cheon, Jaekyung, Oh, Sang-Bo, Ahn, Joong-Bae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608207/ https://www.ncbi.nlm.nih.gov/pubmed/36313033 http://dx.doi.org/10.7150/jca.74107 |
Ejemplares similares
-
Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016) -
How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea
por: Bae, SeungJin, et al.
Publicado: (2022) -
Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors
por: Cheong, Chinock, et al.
Publicado: (2022) -
Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report
por: Baik, Hyungjoo, et al.
Publicado: (2021) -
Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)